Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States

Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men

(2013) Patrick Haentjens   ANNALS OF INTERNAL MEDICINE

Aging and osteoporosis in breast and prostate cancer

(2011) Ari VanderWalde et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke

(2010) Julia H. Hayes et al.   BJU INTERNATIONAL

Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

(2010) Glenn N. Levine et al.   CIRCULATION

Incidence and Mortality of Hip Fractures in the United States

(2009) Carmen A. Brauer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excess mortality following hip fracture: a systematic epidemiological review

(2009) B. Abrahamsen et al.   OSTEOPOROSIS INTERNATIONAL

Incidence and risk factors for low trauma fractures in men with prostate cancer

(2008) Henrik G. Ahlborg et al.   BONE

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer

(2008) Anthony V. D'Amico et al.   CANCER

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

(2008) Celestia S Higano   Nature clinical practice. Urology